323 related articles for article (PubMed ID: 11288962)
1. Angiotensin receptor blockers: evidence for preserving target organs.
Carson P; Giles T; Higginbotham M; Hollenberg N; Kannel W; Siragy HM
Clin Cardiol; 2001 Mar; 24(3):183-90. PubMed ID: 11288962
[TBL] [Abstract][Full Text] [Related]
2. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
Grothusen A; Divchev D; Luchtefeld M; Schieffer B
Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
[TBL] [Abstract][Full Text] [Related]
4. Comparison of type 1 angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the treatment of hypertension.
Weber MA
J Hypertens Suppl; 1997 Dec; 15(6):S31-6. PubMed ID: 9493125
[TBL] [Abstract][Full Text] [Related]
5. Recent changes in the landscape of combination RAS blockade.
Epstein BJ; Smith SM; Choksi R
Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
[TBL] [Abstract][Full Text] [Related]
6. Enhancing cardiac protection after myocardial infarction: rationale for newer clinical trials of angiotensin receptor blockers.
Pfeffer MA
Am Heart J; 2000 Jan; 139(1 Pt 2):S23-8. PubMed ID: 10618584
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin-Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use?
Messerli FH; Bangalore S; Bavishi C; Rimoldi SF
J Am Coll Cardiol; 2018 Apr; 71(13):1474-1482. PubMed ID: 29598869
[TBL] [Abstract][Full Text] [Related]
8. RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection.
Werner C; Baumhäkel M; Teo KK; Schmieder R; Mann J; Unger T; Yusuf S; Böhm M
Clin Res Cardiol; 2008 Jul; 97(7):418-31. PubMed ID: 18454336
[TBL] [Abstract][Full Text] [Related]
9. Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers.
Verdecchia P; Gentile G; Angeli F; Reboldi G
Ther Adv Cardiovasc Dis; 2012 Apr; 6(2):81-91. PubMed ID: 22528743
[TBL] [Abstract][Full Text] [Related]
10. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Kjeldsen SE; Julius S
Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
[TBL] [Abstract][Full Text] [Related]
11. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
[TBL] [Abstract][Full Text] [Related]
12. Renin inhibition--benefit beyond hypertension control.
Kher V
J Assoc Physicians India; 2009 Jul; 57():518-20, 525. PubMed ID: 20329413
[TBL] [Abstract][Full Text] [Related]
13. Theoretical basis and clinical evidence for differential effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor subtype 1 blockers.
Weir MR; Henrich WL
Curr Opin Nephrol Hypertens; 2000 Jul; 9(4):403-11. PubMed ID: 10926177
[TBL] [Abstract][Full Text] [Related]
14. [Angiotensin II receptor blockers--evidence along the cardiovascular continuum].
Zeller A; Battegay E
Praxis (Bern 1994); 2005 Apr; 94(15):581-94. PubMed ID: 15884724
[TBL] [Abstract][Full Text] [Related]
15. Cardiac protection: evolving role of angiotensin receptor blockers.
Califf RM; Cohn JN
Am Heart J; 2000 Jan; 139(1 Pt 2):S15-22. PubMed ID: 10618583
[TBL] [Abstract][Full Text] [Related]
16. [Inhibition of the renin-angiotensin system: ACE inhibitors and angiotensin II receptor blockers].
Pichler M; Klein W; Huber K; Pachinger O
Wien Med Wochenschr; 1996; 146(11):228-31. PubMed ID: 8928520
[TBL] [Abstract][Full Text] [Related]
17. Novel Cardiac Intracrine Mechanisms Based on Ang-(1-12)/Chymase Axis Require a Revision of Therapeutic Approaches in Human Heart Disease.
Reyes S; Varagic J; Ahmad S; VonCannon J; Kon ND; Wang H; Groban L; Cheng CP; Dell'Italia LJ; Ferrario CM
Curr Hypertens Rep; 2017 Feb; 19(2):16. PubMed ID: 28233239
[TBL] [Abstract][Full Text] [Related]
18. [Pathophysiological mechanisms of the renin-angiotensin system and its pharmacologic modification by ACE inhibitors or angiotensin II (type 1) receptor blockers in cardiovascular diseases].
Huber K; Pachinger O; Pichler M; Klein W
Z Kardiol; 1997 Apr; 86(4):239-50. PubMed ID: 9235795
[TBL] [Abstract][Full Text] [Related]
19. Advances in angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs).
Swamy KM; Lin MJ; Sun CM
Mini Rev Med Chem; 2003 Sep; 3(6):621-31. PubMed ID: 12871164
[TBL] [Abstract][Full Text] [Related]
20. [Blockade of the renin-angiotensin system by a combination of ACE inhibitors and AT1 receptor antagonists].
Azizi M
Rev Prat; 2004 Jun; 54(11):1167-74. PubMed ID: 15496022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]